2007 JASN IMPACT FACTOR 7.111	HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP
advanced	CURRENT ISSUE	ARCHIVES	JASN Express	ONLINE SUBMISSION

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Campbell, R. C. Articles by Remuzzi, G. Search for Related Content PubMed PubMed Citation Articles by Campbell, R. C. Articles by Remuzzi, G.

Halting the Progression of Chronic Nephropathy

Ruth C. Campbell^*,, Piero Ruggenenti^*, and Giuseppe Remuzzi^*,

*Mario Negri Institute for Pharmacological Research, Bergamo, Italy; Unit of Nephrology, Azienda Ospedaliera, Ospedali Riuniti di Bergamo, Bergamo Italy; and Division of Nephrology, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama.

Correspondence to Dr. Giuseppe Remuzzi, "Mario Negri" Institute for Pharmacological Research, Negri Bergamo Laboratories, Via Gavazzeni, 11-24125 Bergamo, Italy. Phone: 39-035 319 888; Fax: 39-035 319 331;

ABSTRACT. The incidence of end-stage renal disease (ESRD) is increasing worldwide. In the United States alone, there were 372,000 patients requiring renal replacement therapy in the year 2000 and is expected to rise to 650,000 by the year 2010. The trends in Europe and Japan are forecasted to follow a similar path. These increases represent a significant burden to countries worldwide; not only due to the financial costs of providing ESRD care, but also because of lost productivity and significant morbidity and mortality for the affected patients. There is clearly a pressing need for the aggressive identification and early treatment of patients with nephropathy to prevent progression to ESRD. Research in the last 25 yr has made great advances in the understanding of the progression of chronic renal disease in diabetic and nondiabetic proteinuric nephropathy. There are now effective treatment options that can slow the progression of chronic nephropathies in many individuals, and ongoing research has raised the tantalizing prospect of the reversal of renal disease progression. E-mail: gremuzzi@marionegri.it

This article has been cited by other articles:

				K C Tse, F K Li, S Tang, C S-O Tang, K N Lai, and T M Chan Angiotensin inhibition or blockade for the treatment of patients with quiescent lupus nephritis and persistent proteinuria Lupus, December 1, 2005; 14(12): 947 - 952. [Abstract] [PDF]

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673